Form 4: LIFECORE BIOMEDICAL Director Jason Aryeh Increases Stake with RSU Grant

LIFECORE BIOMEDICAL, INC. Director Jason Aryeh acquired 19,506 shares of common stock through a restricted stock unit grant, increasing his total beneficial ownership to 44,060 shares.

Summary

• Jason Aryeh, a Director of LIFECORE BIOMEDICAL, INC. (LFCR), acquired 19,506 shares of common stock.
• The acquisition occurred on July 15, 2025, and was made through a grant of restricted stock units (RSUs).
• Each restricted stock unit converts into one share of common stock.
• Following this transaction, Jason Aryeh beneficially owns a total of 44,060 shares of common stock.
• The acquired RSUs are set to vest on the earlier of the one-year anniversary of the grant date (July 15, 2026) or the date of the Company's annual meeting of stockholders first held in calendar year 2026, provided that date is no less than 50 weeks from the grant date.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through an RSU grant, is generally viewed positively as it indicates alignment of interests and confidence in the company's future.

Positives

• A director increasing their stake in the company, even through an RSU grant, generally signals confidence in the company's future prospects and aligns management interests with shareholders.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's stock transaction.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape for the biomedical sector.

Stakeholder Impact

• Shareholders may view this transaction positively as it demonstrates a director's continued commitment and increased personal stake in the company's performance.

Next Steps

• The restricted stock units are expected to vest on the earlier of July 15, 2026, or the date of the Company's 2026 annual meeting of stockholders (subject to a minimum 50-week period).

Key Dates

Recommendation

Keywords

LIFECORE BIOMEDICAL, LFCR, Jason Aryeh, Director, Insider Transaction, SEC Form 4, Restricted Stock Units, RSU, Stock Acquisition, Beneficial Ownership